A randomized controlled trial of a smoking cessation smartphone application with a carbon monoxide checker.
Preventive medicine
Respiratory tract diseases
Risk factors
Journal
NPJ digital medicine
ISSN: 2398-6352
Titre abrégé: NPJ Digit Med
Pays: England
ID NLM: 101731738
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
10
2019
accepted:
18
02
2020
entrez:
21
3
2020
pubmed:
21
3
2020
medline:
21
3
2020
Statut:
epublish
Résumé
Evidence of the long-term efficacy of digital therapies for smoking cessation that include a smartphone application (app) is limited. In this multi-center randomized controlled trial, we tested the efficacy of a novel digital therapy for smoking cessation: the "CureApp Smoking Cessation (CASC)" system, including a CASC smartphone app, a web-based patient management PC software for primary physicians, and a mobile exhaled carbon monoxide (CO) checker. A total of 584 participants with nicotine dependence were recruited from October 2017 to January 2018, and allocated 1:1 to the CASC intervention group or the control group. Both groups received a standard smoking cessation treatment with pharmacotherapy and counseling for 12 weeks. Meanwhile, the intervention group used the CASC system, and the control group used a control-app without a mobile CO checker, each for 24 weeks. The primary outcome was the biochemically validated continuous abstinence rate (CAR) from weeks 9 to 24. The main secondary outcome was an extended CAR from weeks 9 to 52. Except for 12 participants who did not download or use the apps, 285 participants were assigned to the intervention group, and 287, to the control. CAR from weeks 9 to 24 in the intervention group was significantly higher than that in the control group (63.9% vs. 50.5%; odds ratio [OR], 1.73; 95% confidence interval [CI], 1.24 to 2.42;
Identifiants
pubmed: 32195370
doi: 10.1038/s41746-020-0243-5
pii: 243
pmc: PMC7067789
doi:
Types de publication
Journal Article
Langues
eng
Pagination
35Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing InterestsK.M., H.T., and K.F. have received honoraria from CureApp, Inc. A.N. received consulting fees from CureApp, Inc. A.N. and K.S. are founders of the CureApp Institute. T.M. is an employee of CureApp, Inc. K.S. and S.S. are founders and shareholders of CureApp, Inc. and patent holders of the CASC. E.H. has a consultation contract as a biostatistician with CureApp, Inc.
Références
Drug Alcohol Depend. 2014 Oct 1;143:87-94
pubmed: 25085225
Nicotine Tob Res. 2017 Aug 1;19(8):990-993
pubmed: 27928047
Addiction. 2005 Mar;100(3):299-303
pubmed: 15733243
JAMA. 2006 Jul 5;296(1):64-71
pubmed: 16820548
J Pers Med. 2014 Jul 18;4(3):412-23
pubmed: 25563359
Lancet. 2015 Dec 5;386(10010):2287-323
pubmed: 26364544
BMJ Open. 2018 Jan 21;8(1):e017105
pubmed: 29358418
JMIR Res Protoc. 2019 Feb 11;8(2):e12252
pubmed: 30741641
Addict Behav. 1999 Mar-Apr;24(2):155-66
pubmed: 10336098
Nicotine Tob Res. 2016 May;18(5):885-91
pubmed: 26718743
J Subst Abuse Treat. 2017 Jan;72:103-110
pubmed: 27449226
J Med Internet Res. 2015 Jan 16;17(1):e17
pubmed: 25596170
JAMA. 2006 Jul 5;296(1):47-55
pubmed: 16820546
Transl Behav Med. 2017 Jun;7(2):292-299
pubmed: 28527027
Lancet. 2011 Sep 17;378(9796):1094-105
pubmed: 21885105
Int J Environ Res Public Health. 2018 Feb 07;15(2):
pubmed: 29414907
Contemp Clin Trials. 2016 Sep;50:157-65
pubmed: 27521811
PLoS Med. 2012 Jan;9(1):e1001160
pubmed: 22291576
Ann Epidemiol. 2009 Nov;19(11):815-22
pubmed: 19457683
JMIR Mhealth Uhealth. 2019 Feb 19;7(2):e12694
pubmed: 30777848
Nicotine Tob Res. 2010 May;12(5):500-7
pubmed: 20335281
Clin Ther. 2007 Jun;29(6):1040-56
pubmed: 17692720
J Med Internet Res. 2019 Apr 26;21(4):e13520
pubmed: 30982776
Psychopharmacology (Berl). 2004 Dec;177(1-2):195-9
pubmed: 15179542
JAMA. 2014 Jan 8;311(2):155-63
pubmed: 24399554
Nicotine Tob Res. 2014 Jun;16(6):766-73
pubmed: 24470633
Cochrane Database Syst Rev. 2019 Oct 22;10:CD006611
pubmed: 31638271
JMIR Mhealth Uhealth. 2017 Apr 25;5(4):e56
pubmed: 28442453